Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001104659-21-068039
Filing Date
2021-05-17
Accepted
2021-05-17 16:05:56
Documents
49
Period of Report
2021-03-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q tm2111673d1_10q.htm 10-Q 374960
2 EXHIBIT 31.1 tm2111673d1_ex31-1.htm EX-31.1 10507
3 EXHIBIT 32.1 tm2111673d1_ex32-1.htm EX-32.1 4880
  Complete submission text file 0001104659-21-068039.txt   3058171

Data Files

Seq Description Document Type Size
4 XBRL INSTANCE DOCUMENT ttnp-20210331.xml EX-101.INS 676606
5 XBRL TAXONOMY EXTENSION SCHEMA ttnp-20210331.xsd EX-101.SCH 31178
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE ttnp-20210331_cal.xml EX-101.CAL 34764
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE ttnp-20210331_def.xml EX-101.DEF 94880
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE ttnp-20210331_lab.xml EX-101.LAB 248452
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ttnp-20210331_pre.xml EX-101.PRE 203915
Mailing Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080
Business Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080 6502444990
TITAN PHARMACEUTICALS INC (Filer) CIK: 0000910267 (see all company filings)

EIN.: 943171940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-13341 | Film No.: 21930411
SIC: 2836 Biological Products, (No Diagnostic Substances)